Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
暂无分享,去创建一个
M. Juan | B. Paiva | J. Pérez-Simón | A. Zabaleta | L. Rosiñol | M. Pascal | M. Mateos | V. Cabañas | Á. Urbano-Ispizua | E. Olesti | C. Fernández de Larrea | S. Inogés | V. González-Calle | L. Lopez-Corral | L. Rodríguez-Lobato | B. Martín-Antonio | M. López-Parra | N. Tovar | A. Oliver-Caldés | J. Sáez-Peñataro | M. Español-Rego | Julio Delgado | S. Varea | J. L. Reguera | R. Jimenez | P. Rodríguez-Otero | J. Moraleda | Felipe Prosper | A. Lopez-Diaz de Cerio | A. Sánchez‐Salinas | Maria Calvo-Orteu | Eulàlia Olesti | Joaquín Sáez-Peñataro | A. López-Díaz de Cerio | A. Sanchez-Salinas
[1] R. Vij,et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. , 2023, The New England journal of medicine.
[2] M. Liedtke,et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results , 2023, Nature Medicine.
[3] S. Montoto,et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. , 2022, The Lancet Haematology.
[4] F. Zhan,et al. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma , 2022, JAMA network open.
[5] H. Goldschmidt,et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma , 2022, Leukemia.
[6] E. Giné,et al. Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation , 2022, Frontiers in Oncology.
[7] E. Giné,et al. Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy , 2021, Journal for ImmunoTherapy of Cancer.
[8] F. Prósper,et al. Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) , 2021, Blood.
[9] Jianfeng Zhou,et al. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials , 2021, Frontiers in Immunology.
[10] Chiung-Yu Huang,et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy , 2021, Blood advances.
[11] S. Jagannath,et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.
[12] Alexandra Martínez-Roca,et al. Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak , 2021, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.
[13] M. Beksac,et al. Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations , 2021, British journal of haematology.
[14] H. Goldschmidt,et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. , 2021, The Lancet. Oncology.
[15] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[16] Z. Berneman,et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma , 2020, Journal of Hematology & Oncology.
[17] E. Giné,et al. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] S. Rives,et al. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial , 2020, Frontiers in Immunology.
[19] G. Gutiérrez-García,et al. A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe , 2020, Bone Marrow Transplantation.
[20] M. Juan,et al. Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma , 2020, Haematologica.
[21] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[23] Hans Erik Johnsen,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.